Leucocyte Nadir and Chemotherapy Efficacy in Breast Cancer
Author Information
Author(s): Poikonen P, Saarto T, Lundin J, Joensuu H, Blomqvist C
Primary Institution: Department of Oncology, Helsinki University Central Hospital
Hypothesis
The study examines the association between leucocyte nadir and prognosis in breast cancer patients receiving adjuvant chemotherapy.
Conclusion
A low leucocyte nadir during chemotherapy is associated with better disease-free survival in breast cancer patients.
Supporting Evidence
- A low leucocyte nadir was associated with a long distant disease-free survival.
- Patients with the highest leucocyte nadir values had the worst outcomes.
Takeaway
If a breast cancer patient has low white blood cell counts during chemotherapy, they might have a better chance of staying cancer-free.
Methodology
The study involved 368 patients treated with six cycles of adjuvant CMF chemotherapy, assessing the impact of leucocyte nadir on survival outcomes.
Limitations
In multivariate analysis, leucocyte nadir did not retain prognostic significance.
Participant Demographics
Patients were node-positive breast cancer patients without distant metastases.
Statistical Information
P-Value
0.02
Confidence Interval
1.04–1.06
Statistical Significance
p=0.02
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website